重组人血管内皮抑制素联合顺铂胸腔内灌注治疗晚期非小细胞肺癌恶性胸腔积液的疗效

Clinical efficacy of pleural perfusion with recombinant human endostatin and cisplatin in advanced non-small cell lung cancer patients with malignant pleural effusion

目的观察重组人血管内皮抑制素联合顺铂胸腔内灌注治疗晚期非小细胞肺癌(NSCLC)合并恶性胸腔积液的临床疗效。方法晚期NSCLC合并恶性胸腔积液患者62例随机均分为两组,经胸腔小导管置管引流术排尽胸腔积液后,胸腔内分别灌注重组人血管内皮抑制素45mg+顺铂40mg/m^2(试验组)或顺铂40mg/m^2(对照组),每周2次,连续3周。比较两组的疗效、不良反应及患者的生活质量。结果试验组有效率为80.65%,高于对照组的51.61%(P<0.05)。试验组患者的生活质量改善率高于对照组(80.65%vs.45.16%)(P<0.05)。两组不良反应相仿(P>0.05)。结论胸腔内灌注重组人血管内皮抑制素联合顺铂治疗晚期NSCLC合并恶性胸腔积液疗效优于单用顺铂,未增加不良反应。

Objective To observe the clinical efficacy of pleural perfusion with recombinant human endostatin and cisplatin in advanced non-small cell lung cancer（NSCLC） patients with malignant pleural effusion.Methods Sixty-two advanced NSCLC patients with malignant pleural effusion were equally randomized into two groups of A（treated with cisplatin 40mg/m2 plus recombinant human endostatin 45mg） and B（treated with cisplatin 40mg/m2 alone）,which were used twice a week for 3 weeks.The efficacy,adverse effects and quality of life（QOL） were compared between two groups.Results The effectiveness rate was higher in group A than that in group B（80.65% vs.51.61%）（P〈0.05）.So did the improvement rate of QOL（80.65% vs.45.16%）（P〈0.05）.The incidence rates of adverse effects in two groups were similar（P〉0.05）.ConclusionPleural perfusion of recombinant human endostatin combined with cisplatin is better than cisplatin alone in the treatment of advanced NSCLC patients with malignant pleural effusion without increase of adverse effects.